Combigene AB (COMBI) - Total Liabilities

Latest as of December 2024: Skr4.30 Million SEK ≈ $462.75K USD

Based on the latest financial reports, Combigene AB (COMBI) has total liabilities worth Skr4.30 Million SEK (≈ $462.75K USD) as of December 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore COMBI shareholders equity momentum to track the company's year-over-year net asset growth rate.

Combigene AB - Total Liabilities Trend (2012–2024)

This chart illustrates how Combigene AB's total liabilities have evolved over time, based on quarterly financial data. See COMBI free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.

Combigene AB Competitors by Total Liabilities

The table below lists competitors of Combigene AB ranked by their total liabilities.

Company	Country	Total Liabilities
ASOS Plc LSE:ASC	UK	GBX1.46 Billion
Wyncoast Industrial Park Public Company Limited BK:WIN	Thailand	฿369.34 Million
BuilderSmart Public Company Limited BK:BSM	Thailand	฿737.57 Million
Itech Minerals Ltd AU:ITM	Australia	AU$369.87K
Narryer Metals Ltd AU:NYM	Australia	AU$156.90K
Gauzy Ltd. Ordinary Shares NASDAQ:GAUZ	USA	$118.95 Million
Signature Resources Ltd V:SGU	Canada	CA$2.45 Million

Liability Composition Analysis (2012–2024)

This chart breaks down Combigene AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see COMBI market cap.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	17.47	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.06	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.06	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Combigene AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Combigene AB (2012–2024)

The table below shows the annual total liabilities of Combigene AB from 2012 to 2024.

Year	Total Liabilities	Change
2024-12-31	Skr4.30 Million ≈ $462.75K	+3.47%
2023-12-31	Skr4.16 Million ≈ $447.22K	-31.86%
2022-12-31	Skr6.10 Million ≈ $656.32K	-23.21%
2021-12-31	Skr7.94 Million ≈ $854.68K	-0.49%
2020-12-31	Skr7.98 Million ≈ $858.87K	-66.06%
2019-12-31	Skr23.51 Million ≈ $2.53 Million	+60.38%
2018-12-31	Skr14.66 Million ≈ $1.58 Million	+801.06%
2017-12-31	Skr1.63 Million ≈ $175.10K	+100.96%
2016-12-31	Skr809.66K ≈ $87.13K	+17.05%
2015-12-31	Skr691.73K ≈ $74.44K	+18.85%
2014-12-31	Skr582.04K ≈ $62.64K	+1320.21%
2013-12-31	Skr40.98K ≈ $4.41K	-86.18%
2012-12-31	Skr296.58K ≈ $31.92K	--

About Combigene AB

ST:COMBI Sweden Biotechnology

Market Cap

$5.24 Million

Skr48.71 Million SEK

Market Cap Rank

#28449 Global

#640 in Sweden

Share Price

Skr2.46

Change (1 day)

+1.23%

52-Week Range

Skr2.32 - Skr2.49

All Time High

Skr152.75